RANKL signaling in bone physiology and cancer.
Current opinion in supportive and palliative care, ISSN: 1751-4266, Vol: 1, Issue: 4, Page: 317-322
2007
- 30Citations
- 19Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations30
- Citation Indexes30
- 30
- CrossRef24
- Captures19
- Readers19
- 19
Review Description
PURPOSE OF REVIEW: Increased osteoclast activity plays an operative role in the pathophysiology of skeletal complications of malignancy. This review focuses on the critical roles of a triad of molecules - receptor activator of nuclear factor kappa beta ligand and its two receptors, receptor activator of nuclear factor kappa beta and osteoprotegerin - in the regulation of osteoclastogenesis across a broad spectrum of cancer-induced bone diseases. RECENT FINDINGS: While it is well established that osteoclastic bone resorption plays an operative role in the skeletal complications of 'osteolytic' bone metastasis, recent evidence has described osteoclasts in osteoblastic prostate cancer metastases and increases in serum markers of bone resorption in these patients. In addition to its essential role in osteoclastogenesis, receptor activator of nuclear factor kappa beta ligand has also been recently shown to increase migration and invasive properties of receptor activator of nuclear factor kappa beta-positive tumor cells, and potentially may play a direct role in the bone tropism of those tumors. SUMMARY: The critical role of receptor activator of nuclear factor kappa beta ligand signaling in regulating osteoclast activity is described in detail in this review, as is its role in cancer-mediated bone destruction, and the potential of receptor activator of nuclear factor kappa beta ligand inhibition as a novel treatment in tumor-induced bone disease.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=55249106214&origin=inward; http://dx.doi.org/10.1097/spc.0b013e3282f335be; http://www.ncbi.nlm.nih.gov/pubmed/18685382; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01263393-200712000-00015; http://journals.lww.com/01263393-200712000-00015
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know